Q-omics provides the consensus-scored RPL34P21 profile across patient tissues and cancer cell-line models. RPL34P21 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPL34P21 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RPL34P21 RNA expression shows 7,301 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where RPL34P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL34P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL34P21 survival associations across molecular data types. RPL34P21 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL34P21 RNA expression–survival associations across cancer types. High RPL34P21 expression shows unfavorable associations in COAD, ACC, THCA, CHOL and KIRC, but favorable associations in UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RPL34P21 RNA expression.
This table summarizes RPL34P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL34P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL34P21 shows lower tumor expression in LUAD and higher tumor expression in HNSC, UCEC, PRAD and LIHC. The HNSC box plot shows higher RPL34P21 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .005).
This table shows molecular features associated with RPL34P21 in patient tissues and cancer cell lines. In patient samples, RPL34P21 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
